

Component Model for Macroscopic Tumour Biomechanics



University of Bern, Institute for Surgical Technology & Biomechanics (ISTB)

CHIC

The Computational Horizons in Cancer (CHIC) [1] project addresses the challenge of **personalised clinical decision support** for **cancer** treatment, based on the integration of multi-modality, multi-scale data. Computational models are developed for this purpose, as well as a secure infrastructure for data and model access, and reuse. CHIC focuses on selected clinical scenarios: Nephroblastoma, Glioblastoma, Non-Small-Cell Lung Cancer and Prostate Cancer.


Cancer is a complex condition involving a large variety of processes on different length and time scales. Challenges related to the development, validation and maintenance of suitable **multi-scale models** are addressed through **hyper-**

Hyper-Modeling in CHIC

Hyper-modeling has been defined as the "general theory and practice of linking system models and their components" [2]. Here, a hyper-model represents a disease model which emerges from the **composition** of **multiple component models**, each of which captures existing knowledge about a portion of the process and operates at characteristic space-time intervals.

This approach facilitates the **collab**orative development of complex disease models and the **re-use of val**idated simulation components.

In CHIC, five mechanistic component models are used. The main model outcomes refer to the cell / tissue scale and are influenced by processes on molecular and tissue



UNIVERSITÄT

BERN

Biomechanical Simulator

Biomechanical Simulator


The Biomechanical Simulator (BMS) is a **component** model for the simulation of bio-mechanical aspects of macroscopic tumour growth. It relies on the Finite Element Method (FEM) to compute mechanical stresses and strains resulting from tumor growth or shrinkage in a patientspecific anatomy [3]. In CHIC, its output is used to guide the direction of tumour expansion by iterative coupled execution with a cellular-automaton based model of tumour cell proliferation and treatment effects, the Onco-Simulator (OS) [4]. Simulation involves two processes:

- 1. **Pre-processing**: Creation of personalised FEM model.
- 2. **Iterative coupled execution** with model of tumour growth dynamics.


Model and pre-processing pipeline are implemented using **Open Source** libraries and software packages (CGAL, VTK, FEBio).

Pre-processing

A pre-processing pipeline **automates** the model **configura**tion process, including the assignment of body-site specific material properties and boundary conditions from simple configuration options. In combination with automatic segmentation tools, this pipeline permits rapid generation of patient-specific FEM models for personalized simulations.



Simulation Tool



- Standalone or MUSCLE-enabled [5]
- Data I/O in VTK format
- FEBio [6] as FEM-backend

Coupled Execution

Interaction between BMS and OS component models:

- Mechanical pressure informs growth direction.
- Steps repeated in each iteration.

٠	Receiving	updated	map of	f tumour	cell	concentrations	from	OS.
---	-----------	---------	--------	----------	------	----------------	------	-----

• **Mapping** from OS domain to BMS simulation domain:

	OS	BMS
Tissues	tumour	tumour & close-by healthy tissue
Discretisation	regular grid	unstructured mesh

• Computation of elements' **growth** from cell concentration c:


$$\epsilon_{\text{growth}} = \left(\frac{c}{c_0}\right)^{1/3} - 1$$

with cell-carrying capacity of tissue c_0 .

• Growth assumed to result in **uniform and isotropic strain** in tissue:

 $\hat{\boldsymbol{\epsilon}} = \hat{\boldsymbol{\epsilon}}_{ ext{mech}} - \mathbb{I} \epsilon_{ ext{growth}}$

• Computation of mechanical stress $\hat{\sigma}$ assuming hyperelastic material $\hat{\boldsymbol{\sigma}} = \lambda \operatorname{Tr}(\hat{\boldsymbol{\epsilon}}) + 2\mu \hat{\boldsymbol{\epsilon}},$ with Lamé constants $\lambda(E,\nu)$ and $\mu(E,\nu)$.



- Computation of pressure $p = \frac{1}{3} \text{Tr}(\hat{\boldsymbol{\sigma}})$
- Computation of direction of "least pressure": $-\frac{\mathbf{V}p}{\|\mathbf{\nabla}p\|}$

Summary

- Macroscopic-continuum model of tumour biomechanics (BMS) introduces directionality in otherwise isotropic tumour growth process (OS).
- Simulator adaptable to different body-sites, provided segmentations and estimates for biomechanical parameters.
- Uncertainty in parameter assumptions, boundary conditions and minimum size of simulation domain for most body-sites.

Outlook

• Model evaluation ongoing: BMS component model and composite hyper-model.

Р

• Model development:

simulation of tumour mass-effect & healthy tissue **invasion** as mechanically-coupled reaction-diffusion model.

• Simulator improvements:

accuracy of parameter exchange between models, remeshing in case of large deformations.

Further Information

- Computational Horizons In Cancer (CHIC): Developing Meta- and Hyper-Multiscale Models and Repositories for In Silico Oncology. URL: http://chic-vph.eu/project/.
- P. A. Fishwick. "Hypermodelling: an integrated approach to dynamic system modelling". In: Journal of Simulation 6.1 (02/2012). 00000, pp. 2-8.
- C. P. May et al. "Coupling biomechanics to a cellular level model: An approach to patient-specific image driven multi-scale and multi-physics tumor simulation". In: Progress in Biophysics and Molecular Biology. Experimental and Computational Model Interactions in Bio-Research: State of the Art 107.1 (10/2011). 00016, pp. 193–199.
- G. Stamatakos et al. "An advanced discrete statediscrete event multiscale simulation model of the response of a solid tumor to chemotherapy: Mimicking a clinical study". In: Journal of Theoretical Biology 266.1 (09/2010), pp. 124-139.
- J. Borgdorff et al. "Distributed multiscale computing with MUSCLE 2, the Multiscale Coupling Library and Environment". In: J. Comput. Sci. 5.5 (09/2014), pp. 719-731.
- S. A. Maas et al. "FEBio: finite elements for biomechanics". In: J Biomech Eng 134.1 (01/2012), p. 011005.

The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement $n^{\circ}600841$.

Latsis Symposium ETH Zurich on Personalized Medicine 27 – 29 June 2016, Zürich